Rigel Pharmaceuticals EV/EBIT RIGL

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2024.

Today, Oct 23, 2026: 9.7×
Peer median: 6.3×

Rigel Pharmaceuticals' EV/EBIT is 9.7× as of Oct 23, 2026.

The median for 10 large drugmakers of a similar size is 6.3×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	9.7×	3.0×	9.9×
2025	6.1×	4.3×	42.6×
2024	30.5×	30.5×	51.1×

Against its peers

Companies in Drug Manufacturers - General nearest Rigel Pharmaceuticals' size, closest first, today.

Company	EV/EBIT
RIGLRigel Pharmaceuticals	9.7×
ABUSArbutus Biopharma	4.9×
AMPHAmphastar Pharmaceuticals	12.2×
COLLCollegium Pharmaceutical	9.4×
OMEROmeros	n/m
CRMDCorMedix	2.3×
ZVRAZevra Therapeutics	2.9×
IRWDIronwood Pharmaceuticals	3.5×
PBYIPuma Biotechnology	15.6×
PCRXPacira BioSciences	7.6×
ANABAnaptysbio	n/m
Peer median	6.3×

Where Rigel Pharmaceuticals ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Rigel Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.